Results 91 to 100 of about 8,581 (194)

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Microbial Biotechnology
The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy‐refractory depression, alcohol use disorder and anorexia nervosa.
Slavica Janevska, Sophie Weiser, Ying Huang, Jun Lin, Sandra Hoefgen, Katarina Jojić, Amelia E. Barber, Tim Schäfer, Janis Fricke, Dirk Hoffmeister, Lars Regestein, Vito Valiante, Johann E. Kufs   +12 more
doaj   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress

Translational Psychiatry
Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population.
Ines Erkizia-Santamaría, Igor Horrillo, Nerea Martínez-Álvarez, Daniel Pérez-Martínez, Guadalupe Rivero, Amaia M. Erdozain, J. Javier Meana, Jorge E. Ortega   +7 more
doaj   +1 more source

Living in the Mycelial World

Topics in Cognitive Science, EarlyView.
Abstract This manuscript documents a systematic ethnomycological analysis of ethnographic archives. Focusing on texts describing human–fungi interactions, I conduct a global, cross‐cultural review of mushroom use, covering 193 societies worldwide. The study reveals diverse mushroom‐related cultural practices, emphasizing the significance of fungi ...
Roope O. Kaaronen
wiley   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 94-108, July 2026.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Psilocybin-assisted therapy for depression: How do we advance the field?

, 2020
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side ...
SL Rossell (14136969), N Strauss (13401207), M Williams (834184), M Ross (13283916), G Murray (9849164), SE Meikle (14865841), P Liknaitzky (14453649), N Thomas (7667738), DJ Castle (11794721)   +8 more
core  

Personalised Perception: The Effect of Personality on the Sensory Effects of Psychedelics

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Psychedelics induce a wide range of sensory distortions and hallucinations (henceforth ‘distortions’). Yet, little is known about factors that influence the occurrence of certain distortions. Extra‐pharmacological variables including personality traits have been found to correlate with the occurrence of different subjective ...
Alexander Boardman, Jai Whelan, Ryan D. Ward   +2 more
wiley   +1 more source

Psilocybin desynchronizes the human brain [PDF]

A single dose of psilocybin, a psychedelic that acutely causes distortions of space–time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials1–4.
Metcalf, Nicholas V, Bender, David A, Scheidter, Kristen M, Perry, Demetrius, Fair, Damien A, Kay, Benjamin P, Gratton, Caterina, Horan, Christine, Whiting, Forrest I, Gordon, Evan M, Lenze, Eric J, Nicol, Ginger E, Padawer-Curry, Jonah A, Raichle, Marcus E, Subramanian, Subha, Schweiger, Julie A, Chen, Yong, Carhart-Harris, Robin, Reneau, T Rick, Krimmel, Samuel R, Laumann, Timothy O, Chacko, Ravi V, Shimony, Joshua S, Dosenbach, Nico UF, Shinohara, Russell T, Yacoub, Essa, Siegel, Joshua S, Moser, Julia, Vizioli, Luca, Wong, Dean F, et al,, Nelson, Steven M, Raison, Charles L, Snyder, Abraham Z   +33 more
core   +1 more source

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans [PDF]

, 2007
Rationale Binocular rivalry occurs when different images are simultaneously presented to each eye. During continual viewing of this stimulus, the observer will experience repeated switches between visual awareness of the two images. Previous studies have
Pettigrew, John D, Vollenweider, Franz X, Pettigrew, JD, Wallis, Guy M, Wallis, Guy M., Vollenweider, FX, Carter, Olivia L, Liu, Guang B., Carter, Olivia L., Liu, GB, Carter, OL, Liu, Guang B, Pettigrew, John D., Vollenweider, Franz X., Wallis, GM, Hasler, Felix, Hasler, F   +16 more
core   +1 more source

Decriminalization of Psilocybin. Initiative Statute.

, 2017
Decriminalizes use, possession, sale, transport, or cultivation of psilocybin (a hallucinogenic compound) by persons at least 21 years of age. Summary of estimate by Legislative Analyst and Director of Finance of fiscal impact on state and local ...

core   +2 more sources